- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07315100
Navigated Partial Nephrectomy
Image-guided Navigation During Robot-assisted Partial Nephrectomy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Robot-assisted partial nephrectomy (RAPN) is now the preferred option for treatable renal lesions due to its ability to preserve kidney function while effectively treating cancer. Despite RAPN's effectiveness, its surgical complexity and varied approach requirements pose challenges. Image-guided surgery applies pre-operative imaging for patient-specific intra-operative visualization of the kidney and lesion margins to support the surgeon during resection. However, adapting to surgery-induced deformations remains a challenge. An approach that is able to correct for organ movements during surgery might result in an optimal preservation rate of healthy kidney parenchyma and improved decisiveness for the surgeon during resection. On the long term, this might result in a larger shift from radical to partial nephrectomies, leading to patients with improved renal functions after lesion resection.
The primary objective is to assess the ability to achieve preoperatively planned resection volumes by adding EM tracked navigation in RAPN, as minimizing the removal of healthy kidney tissue is challenging nowadays. A deviation within 35% between the planned and actual resection volumes is considered comparable and therefore deemed successful. Secondary objectives are the time for localizing and removing the renal lesion, the impact on surgical decisiveness, and the clinical and technical success of implementing the navigation setup.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Holland
-
Amsterdam, North Holland, Netherlands, 1066 CX
- Netherlands Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Patient provides written informed consent form
- Patient is scheduled for robot-assisted partial nephrectomy
Exclusion Criteria:
- Ferro-magnetic implants or other factors in the abdominal or thoracic area that could influence image quality
- Pacemaker or defibrillator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patients scheduled for robot-assisted partial nephrectomy
This study is designed as a single-center prospective feasibility study to evaluate the precision of EM tracking navigation in RAPN.
We plan to conduct this study over a period of approximately 1 year.
Eligible participants are patients who are scheduled for RAPN at the NKI-AvL, without restrictions on the pathology type of the lesions targeted for removal.
Patients are informed about the study before the planned surgery and, after being provided with the necessary information regarding participation in the study, will be asked for informed consent.
Participation in the study concludes at the end of the surgical procedure.
|
Diagnostic CT and MRI scans are used to create a 3D digital model to illustrate the lesion's relation to the kidney and surrounding anatomy.
The surgeon reviews this model, validates the segmentation, and plans the resection volume.
The surgical procedure proceeds according to standard protocols in a standard operational setting, with the addition of navigation tools.
A sterile EM sensor is inserted through a separate 5mm trocar and affixed to the kidney in proximity to the lesion in a region intended to be resected.
Registration of the 3D model is conducted using an EM pointer or a tracked instrument, pointing to identifiable anatomical landmarks or structures on the kidney to validate accuracy.
Both the digital model and the location of tracked instruments are displayed in real-time to the surgeon in the video console of the robot, allowing real-time navigation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Accuracy of the EM navigation setup in preserving the volume of renal tissue designated for resection prior to surgery
Time Frame: One day
|
The planned resection volume will be compared to the actual resected volume using CT scan data.
A navigation is deemed successful if comparable resection volumes are measured.
The criteria for comparable resection volume measurement is defined as a discrepancy of no more than 35% between the preoperative and post-operative volumes, ensuring that the navigation aids in achieving precision in surgical outcomes.
The study is successful when 70% of the navigations (i.e. 14 out of 20 patients) are successful.
|
One day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time required for navigation implementation
Time Frame: One day
|
One day
|
|
Clinical success of number of negative resection margins
Time Frame: One day
|
One day
|
|
Technical usability of the navigation setup using post-operative questionnaires for surgeons
Time Frame: One day
|
One day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Theo Ruers, The Netherlands Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urologic Neoplasms
- Kidney Neoplasms
- Surgical Procedures, Operative
- Surgery, Computer-Assisted
Other Study ID Numbers
- N24NPN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cancer
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
National Cancer Institute (NCI)TerminatedSorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney CancerClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Papillary Renal Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedStage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer AJCC v8 | Stage III Renal Pelvis and Ureter Cancer AJCC v8 | Stage IV Renal Pelvis and Ureter Cancer AJCC v8 | Stage 0a Renal Pelvis and Ureter Cancer AJCC v8 | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
Case Comprehensive Cancer CenterCompletedClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
National Cancer Institute (NCI)TerminatedRenal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
Spanish Oncology Genito-Urinary GroupAdknoma Health ResearchCompletedRenal Cell Cancer MetastaticSpain
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Cancer | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Healthy Subject | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
Clinical Trials on Image guided surgery
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingGynecologic Cancer | Lymph Node MetastasisItaly
-
LumaMedUniversity of Wisconsin, MadisonUnknownBreast CancerUnited States
-
NYU Langone Health7D Surgical Inc.WithdrawnScoliosis | Spinal Stenosis | Spondylolisthesis
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer
-
University Hospital Plymouth NHS TrustCompletedHepatocellular Carcinoma | Liver Cancer | Liver Metastasis Colon CancerUnited Kingdom
-
St. Jude Children's Research HospitalLance Armstrong FoundationActive, not recruitingSoft Tissue Sarcoma | Rhabdomyosarcoma | Sarcoma, Ewing's | Musculoskeletal TumorsUnited States
-
University Health Network, TorontoNot yet recruiting
-
University Health Network, TorontoRecruiting
-
Instituto do Cancer do Estado de São PauloAngiodynamics, Inc.Recruiting